Physician profile
Raghava Reddy Induru
NPI 1063608388
$624,975.56
in general payments reported to CMS, 2019-2025
13 companies · $168K in 2025
The $168K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $37K · 2021: $70K · 2022: $105K · 2023: $127K · 2024: $76K · 2025: $168K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Travel and Lodging: $38K · Consulting Fee: $21K · Food and Beverage: $5,278 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $305,259.25 |
| Travel and Lodging | $38,103.80 |
| Consulting Fee | $21,368.00 |
| Food and Beverage | $5,278.10 |
| Education | $157.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $218,506.97 | 2019-2025 | Opdivo, Krazati |
| Astrazeneca Pharmaceuticals Lp | $155,277.33 | 2019-2025 | Datroway, Tagrisso, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $153,766.97 | 2022-2025 | Libtayo |
| Genzyme Corporation | $31,430.43 | 2021-2023 | |
| Daiichi Sankyo INC. | $27,013.40 | 2022-2025 | Datroway, Enhertu |
| Mirati Therapeutics, INC. | $19,409.33 | 2023 | Krazati |
| Regeneron Pharmaceuticals, INC. | $16,756.21 | 2022-2023 | Libtayo |
| Seagen INC. | $1,500.00 | 2019 | |
| F. Hoffmann-La Roche Ag | $1,185.40 | 2019 | |
| Rigel Pharmaceuticals, INC. | $88.55 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Gilead Sciences, INC. | $28.97 | 2025 | Trodelvy |
| Pfizer INC. | $12.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghava Induru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.